Title:
DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND
Document Type and Number:
WIPO Patent Application WO/2021/073491
Kind Code:
A1
Abstract:
A dihydroimidazo pyrimido pyrimidinone compound of Formula I, or a pharmaceutical salt of the compound, or a prodrug thereof. The compound is a Wee1 kinase inhibitor and is applicable in treating diseases caused by abnormal Wee1 activity.
Inventors:
CAI SUI XIONG (CN)
TIAN YE EDWARD (CN)
WANG XIAO ZHU (CN)
TIAN YE EDWARD (CN)
WANG XIAO ZHU (CN)
Application Number:
PCT/CN2020/120569
Publication Date:
April 22, 2021
Filing Date:
October 13, 2020
Export Citation:
Assignee:
IMPACT THERAPEUTICS INC (CN)
International Classes:
A61K31/519; C07D487/14; A61K31/5377; A61K45/06; A61P35/00; A61P35/02; C07D471/14; C07D519/00
Domestic Patent References:
| WO2018090939A1 | 2018-05-24 | |||
| WO2005021551A1 | 2005-03-10 | |||
| WO2019011228A1 | 2019-01-17 |
Foreign References:
| CN103703005A | 2014-04-02 |
Other References:
TONG YUNSONG ET AL.: "Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 1, 6 August 2014 (2014-08-06), XP055165188, ISSN: 1948-5875, DOI: 10.1021/ml5002745
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC (CN)
Download PDF: